BackReata Pharmaceuticals Overview

Reata Pharmaceuticals Long Term Debt

Track Reata Pharmaceuticals's long-term debt ($160M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$163.55M

Peer average / median

Loading

Reata Pharmaceuticals Long Term Debt History

Loading

Reata Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Reata Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Reata Pharmaceuticals (RETA) FAQ

As of the most recent data (June 2023), RETA shows a long-term debt of $160M. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RETA's long-term debt is now $160M (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Reata Pharmaceuticals is outperforming or lagging.

Tracking RETA's long-term debt over time shows whether Reata Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $160M In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Reata Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $160M) with ownership activity and broader fundamentals.

Reata Pharmaceuticals's long-term debt is $160M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.